Riomet

• Adrenergic alpha-Agonists
• Antihypertensive Agents
• Sympatholytics
• ATC:C02AB01
• ATC:C02AB02

• Apo-Metformin
• Fortamet
• Gen-Metformin
• Glucophage
• Glucophage XR
• Glycon
• Metformin HCL
• Novo-Metformin
• Nu-Metformin
• Riomet
• metformin hydrochloride

• No information avaliable

C₁₀H₁₃NO₄

http://www.rxlist.com/cgi/generic2/methyl.htm

Riomet FDA

Riomet MSDS

No information avaliable

211.215 g/mol

300 ^oC

1000 mg/L

Solid

-1.849

Liquid for injection; Tablets for oral use (125 mg, 250 mg, or 500 mg)

For use in the treatment of hypertension.

Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Only methyldopa, the L-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the antihypertensive activity appears to be due solely to the L-isomer. About twice the dose of the racemate (DL-alpha-methyldopa) is required for equal antihypertensive effect. Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration. In some patients the heart rate is slowed. Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy. Methyldopa reduces both supine and standing blood pressure. Methyldopa usually produces highly effective lowering of the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur.

Absorption from the gastrointestinal tract is variable but averages approximately 50%.

The oral LD₅₀ of methyldopa is greater than 1.5 g/kg in both the mouse and the rat. Symptoms of overdose include bloating, constipation, diarrhea, dizziness, extreme drowsiness, gas, light-headedness, nausea, severely low blood pressure, slow heartbeat, vomiting, and weakness.

No information avaliable

Humans and other mammals